Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
Pancreatic Cancer Exceptional Responders and the Immune System Link
Dr. Vinod Balachandran looks at the immune system of exceptional responders--patients who respond extremely well to chemotherapy--for treatment clues.
Testing a Different Approach to Pancreatic Cancer Treatment
A pancreatectomy or Whipple procedure can remove a patient’s main tumor, but post-surgical testing of lymph nodes and the edges…
Genetic Testing for All Pancreatic Cancer Patients
A study by Dr. Gloria Petersen's research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Molecular Sequencing Leads to Customized Treatment
When Florida resident Doron Broman was diagnosed with stage IV pancreatic cancer, his decision to get treated in Boston gave him access a PARP inhibitor for maintenance.
Personalized Immunotherapy Vaccine for Pancreatic Cancer
Researchers are creating personalized vaccines to stimulate a pancreatic cancer patient's immune system after surgery and chemotherapy.
Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Due to numerous factors, including rising rates of obesity and smoking, for example, pancreatic cancer jumped to number three, and…
